tVNS for depression

This page is intended for UK healthcare professionals. Clinical information, including dosing parameters, effect sizes, and trial-level data, is included.

The clinical context

Major depressive disorder is among the most prevalent and disabling conditions worldwide. In the UK, roughly 1 in 6 adults experiences depression at any given time. Approximately 30% of patients with MDD do not achieve adequate symptom control with standard pharmacotherapy, a condition termed treatment-resistant depression (TRD), typically defined as failure to respond to two or more adequate trials of antidepressant medication.

Real-world data underscore the challenge. In a European cohort study of 411 patients with treatment-resistant depression, only 16.7% achieved remission after six months on a new antidepressant, rising to just 19.2% at twelve months (Heerlein et al., 2021).

Beyond treatment resistance, many patients who do respond to antidepressants experience burdensome side effects: weight gain, sexual dysfunction, emotional blunting, and gastrointestinal disturbance. These contribute to poor adherence and treatment discontinuation.

Existing neuromodulation options each have practical limitations. ECT offers the highest acute response rates but requires general anaesthesia and carries cognitive side effects. rTMS is effective but requires daily clinic attendance for four to six weeks. Ketamine/esketamine raises concerns about durability, abuse potential, and cost.

tVNS occupies a distinctive position: home-based, self-administered, engaging multiple neurobiological pathways simultaneously, with a response that builds over weeks to months.

Neurobiological mechanisms

The antidepressant mechanism of tVNS is multifactorial, engaging overlapping pathways directly relevant to depression pathophysiology.

Monoamine pathways

Vagal afferents project from the NTS to the locus coeruleus (norepinephrine) and the raphe nuclei (serotonin). A head-to-head trial comparing taVNS with citalopram (Li et al., 2022, n=107) demonstrated that both treatments increased peripheral blood levels of serotonin, dopamine, GABA, and noradrenaline, with no significant between-group differences. This provides direct biochemical evidence that tVNS engages the same neurotransmitter systems targeted by conventional antidepressants.

HPA axis modulation

Depression is associated with chronic HPA axis activation. Research on implanted VNS demonstrated that CRH/ACTH responses normalised after VNS treatment (O'Keane et al., 2005). Neuroimaging studies of tVNS show deactivation of the hypothalamus during stimulation.

Cholinergic anti-inflammatory pathway

Patients with MDD consistently show elevated pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). tVNS engages the inflammatory reflex via the cholinergic anti-inflammatory pathway. In a clinical trial of 35 patients, the taVNS group showed significant reductions in normalised aggregate pro-inflammatory cytokines and IL-6 levels compared with sham, and each 1 pg/mL reduction in IL-6 correlated with a 0.798-point improvement in clinical outcomes.

Neuroplasticity

VNS drives expression of brain-derived neurotrophic factor (BDNF) and increases phosphorylation of the BDNF receptor TrkB. BDNF levels are characteristically reduced in depression and increase with successful antidepressant treatment. This neuroplasticity-promoting effect may underpin the slow but sustained antidepressant response.

Network-level effects

Neuroimaging in tVNS-treated MDD patients demonstrates decreased default mode network (DMN) functional connectivity (characteristically overactive in depression), increased amygdala to dorsolateral prefrontal cortex connectivity, and modulation of the salience network.

Clinical evidence

Hein et al. (2013): first RCT

37 patients, sham-controlled, 2 weeks. Stimulation at 1.5 Hz, 0.13 mA. BDI reduction: 12.6 points (active) vs 4.4 (sham), p=0.004. No significant difference on clinician-rated HAMD. Limited by small sample, short duration, and unusually low stimulation parameters.

Rong/Kong et al. (2016): largest pilot study

160 MDD patients across two cohorts. 20 Hz, 200 microsecond pulse width, 4 to 6 mA, 30 minutes twice daily at the cymba conchae.

Week 4 HAMD-24: 16.0 vs 20.6 (effect size 0.57, p < 0.0001)
Week 4 response rate: 27% vs 0% (p < 0.00001)
Week 8 response rate: 53%
Week 12 response rate: 80%
Week 12 remission rate (HAMD < 8): 39%

Two observations stand out. First, the response rate built substantially over time, from 27% at week 4 to 80% at week 12. Second, the effect size of 0.57 at four weeks is clinically meaningful.

Limitations: non-randomised, sequential cohort allocation, single-blind, predominantly Chinese population.

Li et al. (2022): taVNS vs citalopram

107 patients randomised to taVNS (n=55, 8 weeks) or citalopram (n=52, 12 weeks, 40 mg/day). No significant group-by-time interaction on HAM-D17 (p=0.79). taVNS produced significantly higher remission rates at weeks 4 and 6 compared with citalopram. Both treatments produced significant increases in serotonin, dopamine, GABA, and noradrenaline. Absence of a sham arm means placebo effects cannot be excluded from either group.

DELOS-1 (2022): peripartum depression

25 women with MDD with peripartum onset, open-label. Week 6 HAM-D17 change: -9.7. Response rate 74%, remission rate 61%. A population where non-pharmacological options are particularly valued.

Liu et al. (2024): post-stroke depression

Double-blind, randomised, placebo-controlled. taVNS combined with conventional treatment significantly reduced HAMD scores, with evidence of amygdala to DLPFC connectivity changes.

iWAVE pilot (2025): accelerated inpatient protocol

10 psychiatric inpatients. Accelerated taVNS significantly reduced PHQ-9 (mean reduction -6.00, p < 0.05), BDI (-11.00), GAD-7 (-5.90), and BAI (-9.40).

Meta-analyses

Tan et al. (2023, 12 RCTs, 838 participants): taVNS significantly improved depression scores, with higher response rates than sham and comparable rates to antidepressants. Evidence rated low to very low by GRADE.

Li et al. (2024, 5 human studies, 306 patients): concluded that while feasibility and positive signals exist, "it is still inconclusive whether taVNS is clinically effective to treat depression."

Implanted VNS context

The implanted VNS evidence base is important context. Aaronson et al. (2017, 5-year registry, 795 patients):

5-year cumulative response rate: VNS + TAU 67.6% vs TAU alone 40.9%
5-year cumulative remission rate: VNS 43.3% vs TAU 25.7%
Duration of remission: VNS 40 months vs TAU 19 months
Among ECT non-responders, VNS still achieved 59.6% response

The RECOVER trial (2024, n=493, sham-controlled) did not meet its primary endpoint, though significant benefits were observed on multiple secondary endpoints.

Stimulation parameters

Parameter	Range across trials	Most used in depression
Frequency	1.5 to 120 Hz	20 to 25 Hz
Pulse width	200 to 500 microseconds	200 to 500 microseconds
Intensity	Sub-pain threshold	Maximum tolerated (typically 4 to 6 mA)
Duty cycle	Continuous or 30s on/off	Continuous
Daily duration	15 min to 4 hours	30 min twice daily
Ear	Left	Left

The most commonly used depression protocol (Rong/Kong): 20 Hz, 200 to 500 microsecond pulse width, 4 to 6 mA titrated to sensory threshold, 30 minutes twice daily at the left cymba conchae.

There is currently no consensus on optimal parameters. The AddVNS study (protocol published 2026) represents the first well-designed trial specifically aiming to elucidate optimal parameters and biological mechanisms.

Predicting response

Low baseline HRV (RMSSD): patients with low vagal tone show the greatest improvement (Translational Psychiatry, 2025).
fMRI-based prediction: resting-state fMRI with machine learning has demonstrated feasibility of neuroimaging-guided patient selection (2024 study, 86 MDD patients).
Severity: strongest clinical data is for mild to moderate depression. Evidence for severe TRD is limited for transcutaneous approaches.
Inflammatory profile: theoretical rationale for greater benefit in patients with elevated CRP/IL-6, though not formally tested in taVNS trials.

Safety

No serious device-related adverse events were reported in the controlled depression trials cited here. Common mild and transient effects (up to 20 to 25%): local skin erythema, tingling, itching, headache, dizziness. Less common: tinnitus (resolves on cessation), nausea. The Instructions for Use list a fuller range and note that some patients may experience a preliminary worsening of depression early in treatment.

A systematic review of the safety and tolerability of tVNS (Redgrave et al., 2018; 51 studies, 1,322 participants) concluded that tVNS is safe and well tolerated at the doses tested to date. The most common side effect was local skin irritation from the electrode (18.2%); 35 participants (2.6%) withdrew because of side effects; and of the serious adverse events recorded, only 3 (across 1,322 participants) were judged possibly related to tVNS, with symptomatic bradycardia in 1 (0.08%).

Practical guidance for UK clinicians

Candidate selection

Adults with MDD who have not responded to at least one adequate trial of antidepressant medication
Patients seeking non-pharmacological or adjunctive options
Patients unable to access or tolerate rTMS or ECT
Peripartum depression where non-pharmacological approaches are preferred
Exclusions (per the IFU): pregnancy; active implants (cardiac pacemaker, implanted vagus nerve stimulator, cochlear implant); cerebral shunt; sore, broken, or diseased skin at the site. Cardiac arrhythmia warrants medical clearance before use (a caution, not an absolute exclusion).

Treatment initiation

Consider maintaining stable medication regimen during initial assessment period
Titrate intensity to maximum tolerated (just below pain threshold), typically 4 to 6 mA
25 Hz (the tVNS E delivers a fixed 25 Hz), 200 to 500 microsecond pulse width, 30 minutes twice daily
Assess response at 4, 8, and 12 weeks using PHQ-9 or HAMD
Allow at least 8 to 12 weeks before judging response

Patient counselling

Benefit typically becomes apparent from 4 to 8 weeks, with continued improvement through 12 weeks
Response rates of 27 to 80% and remission rates of 39 to 61% have been reported, though these come predominantly from open-label designs and are likely inflated
Mild local side effects are expected and generally well tolerated
The device is an adjunct. Medication changes should be discussed with the prescribing clinician
Building sessions into a daily routine (reading, watching television, resting) aids adherence

Regulatory status

The tVNS E device holds Class IIa certification under EU MDR 2017/745 with depression as a specifically listed indication. There is currently no NICE interventional procedure guidance or technology appraisal specifically for tVNS in depression. NICE guidance on rTMS for depression (IPG542) exists, but equivalent guidance for tVNS has not been issued.

Key evidence gaps

No large sham-controlled RCT in Western populations. The AddVNS study aims to address this.
Sham control design remains problematic (paresthesia unblinds participants).
No consensus on optimal parameters.
Longest controlled follow-up for taVNS in depression is 12 weeks.
Most evidence from Chinese populations. Generalisability to UK/European populations requires confirmation.
No head-to-head comparisons with rTMS, tDCS, or other non-invasive neuromodulation.

This page is based on evidence available up to April 2026.

tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.